Chicca, Andrea; Bátora, Daniel; Ullmer, Christoph; Caruso, Antonello; Grüner, Sabine; Fingerle, Jürgen; Hartung, Thomas; Degen, Roland; Müller, Matthias; Grether, Uwe; Pacher, Pal; Gertsch, Jürg (2024). A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies. ACS pharmacology & translational science, 7(8), pp. 2424-2438. ACS Publications 10.1021/acsptsci.4c00269
|
Text
chicca-et-al-2024-a-highly-potent-orally-bioavailable-pyrazole-derived-cannabinoid-cb2-receptor-selective-full-agonist.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
The cannabinoid CB2 receptor (CB2R) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. To thoroughly investigate the role of CB2R in pathophysiological conditions and for target validation in vivo, optimal pharmacological tool compounds are essential. Despite the sizable progress in the generation of potent and selective CB2R ligands, pharmacokinetic parameters are often neglected for in vivo studies. Here, we report the generation and characterization of a tetra-substituted pyrazole CB2R full agonist named RNB-61 with high potency (K i 0.13-1.81 nM, depending on species) and a peripherally restricted action due to P-glycoprotein-mediated efflux from the brain. 3H and 14C labeled RNB-61 showed apparent K d values of <4 nM toward human CB2R in both cell and tissue experiments. The 6,800-fold selectivity over CB1 receptors and negligible off-targets in vitro, combined with high oral bioavailability and suitable systemic pharmacokinetic (PK) properties, prompted the assessment of RNB-61 in a mouse ischemia-reperfusion model of acute kidney injury (AKI) and in a rat model of chronic kidney injury/inflammation and fibrosis (CKI) induced by unilateral ureteral obstruction. RNB-61 exerted dose-dependent nephroprotective and/or antifibrotic effects in the AKI/CKI models. Thus, RNB-61 is an optimal CB2R tool compound for preclinical in vivo studies with superior biophysical and PK properties over generally used CB2R ligands.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Chicca, Andrea, Gertsch, Jürg |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
2575-9108 |
Publisher: |
ACS Publications |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
16 Aug 2024 08:02 |
Last Modified: |
16 Aug 2024 08:12 |
Publisher DOI: |
10.1021/acsptsci.4c00269 |
PubMed ID: |
39144568 |
BORIS DOI: |
10.48350/199742 |
URI: |
https://boris.unibe.ch/id/eprint/199742 |
Actions (login required)
 |
Edit item |